Eli Lilly Receives FDA Approval for Zepbound in Moderate-to-Severe Obstructive Sleep Apnea

Eli Lilly and Company today announced that the FDA has approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This marks the first FDA-approved medication for OSA and represents a new treatment paradigm for this condition. In the Phase 3 SURMOUNT-OSA trials, tirzepatide demonstrated significant reductions in apnea-hypopnea index events per hour, with many patients achieving disease resolution. The approval expands Zepbound's indications beyond obesity and type 2 diabetes, demonstrating the broad therapeutic potential of GIP/GLP-1 receptor agonism.